Vicarious Surgical Inc. — Cyborg Score 3/10

Strategic Profile

Founded in 2014, Vicarious Surgical is developing a disruptive technology with the intent of expanding the access of robotic minimally invasive surgery while reducing the cost to treat surgical patients. With an impressive 28 sensors per arm, the robot is designed to replicate a surgeon's natural upper body movements, from shoulders to elbows to wrists. The company has received FDA Breakthrough Device Designation but remains pre-commercial.

Cyborg Score Rationale

The company is expected to run out of cash by early FY26 unless there are significant reductions in cash burn or new financing is secured, with only $13.4M in cash and anticipated cash burn of $50M for FY25. Development timelines have been extended, with 'design freeze' now targeted for the end of FY26 instead of mid-FY26. While the technology is innovative, the company faces serious liquidity challenges and developmental delays.

Top Insights

• Cash burn expected to run out by early FY26 unless significant reductions occur or new financing secured
• Design freeze timeline extended to end of FY26 from mid-FY26
• The Vicarious Surgical System has not been cleared by the FDA and is not available for commercial sale in the United States
• The Vicarious System is the first surgical robotic system to receive Breakthrough Device Designation from the FDA

Named Competitors

• da Vinci Surgical System — Multi-port robotic surgical system with established market dominance
• Hugo RAS — Multi-port robotic-assisted surgical platform
• Versius System — Compact modular robotic surgical system

Recent Developments

• (February 2026) Upcoming earnings report Feb 26, 2026
• (December 2025) Filed $100M mixed securities shelf registration
• (November 2025) Q3 2025 earnings reported with -$1.91 EPS, beating consensus estimate

Open the full interactive Vicarious Surgical Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.